Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of DP1038, an Intranasal Formulation of Octreotide Acetate, in Healthy Volunteers

Matteo Levisetti¹, Olivier Laurent⁴, Mark Daniels¹, Mark Milad², Michelle Mazzoni¹, Joel Martin¹
¹Dauntless Pharmaceuticals Incorporated, San Diego, CA; ²Milad Pharmaceutical Consulting LLC

BACKGROUND

• Octreotide is a synthetic octapeptide analog of naturally occurring somatostatin, with similar pharmacological effects but a longer duration of action, that inhibits the pathological secretion of growth hormone (GH) from pituitary adenomas and of serotonin and other hormones by tumors of the gastrointestinal and endocrine system⁹,¹⁰
• Depot formulations of octreotide and the somatostatin analog, lanreotide, which are administered by subcutaneous (SC) injections, respectively, play a key role in the treatment of neuroendocrine tumors and acromegaly. An immediate release formulation of octreotide for SC administration (Sandostatin) is also available for the management of diarrhea and flushing associated with carcinoid syndrome and the treatment of acromegaly⁹,¹⁰
• DP1038 is a short-acting, non-invasive, intranasal (NAS) formulation of octreotide acetate that includes the novel excipient 1-O-d-octadecyl-2,3-dimethylpropylene (DDM) for enhanced intranasal absorption. DP1038 has the potential to provide therapeutic benefits as an essentially painless, needle-free, safe, and efficacious presentation of octreotide.

OBJECTIVE

• The aim of the study was to determine the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of intranasal octreotide (DP1038) in healthy volunteers.

METHODS

• Two-part, Phase 1, randomized, crossover design study to evaluate varying doses of a novel NAS formulation for octreotide (DP1038) compared to SC octreotide.

Study Part 1 – Safety, Tolerability, and PK

• 4×4 modified Latin square design
• n=10/group (12 total)
• Sandostatin® Injection SC 100 µg
• Intranasal doses selected to cover range of SC doses of 100–1000 µg
• Four-way crossover modified Latin square design, in which each of the 12 subjects enrolled received three single NAS administrations of DP1038 (each at a different dose level: 400, 1200, and 2000 µg), plus a single SC administration of 100 µg Sandostatin Injection, with a one-day washout period between the doses.
• Results from Part 1 were used to identify the NAS DP1038 dose for which the systemic octreotide exposure was similar to that of the 100 µg SC dose of Sandostatin Injection.

Study Part 2 – Safety, Tolerability, PK, and PD

• Crossover study design between Sandostatin injection and intranasal dose determined from Part 1
• n=10/group (20 total)
• PD assessment is GHRH/arginine challenge

• DP1038 1200 µg dose was further assessed in a new set of 20 healthy subjects in a phase 2 study (each at different dose level: 300, 1200, 1800 µg).

RESULTS

DP1038 Demonstrates Rapid Onset and Dose-Proportional PK

• Greater than 95% suppression of GHRH/Arginine stimulated GH production (AUC₀₋∞) was measured with both intranasal DP1038 (1200 µg) and SC Sandostatin (100 µg).
• The plasma octreotide relative bioavailability of 400, 1200, and 2000 µg intranasal doses of DP1038 compared to SC 100 µg Sandostatin Injection was calculated to be between 21.5% and 41.6%. The relative bioavailability of DP1038 to SC Sandostatin is shown in the following table.

Pharmacokinetics:

<table>
<thead>
<tr>
<th>Dose (µg)</th>
<th>Relative Bioavailability %</th>
</tr>
</thead>
<tbody>
<tr>
<td>400</td>
<td>21.5%</td>
</tr>
<tr>
<td>1200</td>
<td>41.6%</td>
</tr>
<tr>
<td>2000</td>
<td>37.5%</td>
</tr>
</tbody>
</table>

Safety:

• Both study parts – Most Common Drug-Related Adverse Events

<table>
<thead>
<tr>
<th>Event</th>
<th>DP1038 400 µg</th>
<th>DP1038 1200 µg</th>
<th>SC 100 µg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal Discomfort</td>
<td>5 (41.7%)</td>
<td>5 (41.7%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Headache</td>
<td>5 (41.7%)</td>
<td>5 (41.7%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>5 (41.7%)</td>
<td>5 (41.7%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5 (41.7%)</td>
<td>5 (41.7%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>5 (41.7%)</td>
<td>5 (41.7%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

• Administration of single doses of 400-2000 µg intranasal DP1038 and 100 µg SC Sandostatin was safe and well tolerated in healthy adult subjects.
• No discontinuations due to adverse events (AEs) or serious AEs.
• Most commonly occurring AEs:
  - Expected and consistent with SC product prescribing information (e.g., loose stools, nausea, and headaches).
  - No, local tolerability events.

CONCLUSIONS

• Intranasal delivery of octreotide (DP1038) results in octreotide PK characteristics comparable to SC octreotide injection and achieves drug concentration levels known to be therapeutic.
• DP1038 exerts robust suppression of basal and GHRH/Arginine stimulated GH secretion in healthy volunteers.
• DP1038 is well tolerated; no significant safety findings were reported.
• DP1038 is useful for the treatment of patients with neuroendocrine tumors and acromegaly.

REFERENCES

1. Brzez et al., Science 179(4068), 77-79 (1972)